Plain Language Summary {#S0001}
======================

Colorectal cancer (CRC) is one of the most common cancers in the United States. Hospitalizations while receiving anticancer treatments (such as chemotherapy) can reduce the effectiveness of treatment. Understanding the rates and drivers for unplanned chemotherapy-related hospitalizations is important when considering treatment choices, later lines of therapy, and clinical course.

In an analysis of administrative claims data, a cohort of 717 patients (mean age 55y; 58% male) with metastatic CRC was identified who received at least one of the five most frequently used first-line chemotherapy agents for CRC (fluorouracil, oxaliplatin, bevacizumab, irinotecan, or capecitabine). A substantial proportion of patients (40%) were hospitalized while receiving chemotherapy (hospitalization proportions by drug: 40% 5-fluorouracil, 38% oxaliplatin, 42% bevacizumab, 49% irinotecan, 39% capecitabine). An ECOG performance status ≥1 was positively associated with the occurrence of a hospitalization; no other patient demographic or clinical characteristics affected hospitalization rates. Hospital stays were typically short and associated with infections, neutropenia, or bowel-related complications.

These data provide an overview of the range of expected hospitalization rates associated with some of the first-line systemic therapies for metastatic CRC. This information may be useful during patient discussions to broadly quantify the risks of hospitalization from first-line chemotherapy and develop anticipatory intervention plans to mitigate adverse events.

Introduction {#S0002}
============

As the third most common cancer in the United States[@CIT0001] -- and the second leading cause of cancer-related deaths[@CIT0002] -- colorectal cancer (CRC) has a substantial impact on patients, healthcare resource utilization, and costs. Hospitalizations while receiving anticancer treatments (such as chemotherapy) can lead to dose delays or reductions that reduce the effectiveness of treatment, and may also expose patients to the risk of infection and increase financial and caregiver burden.[@CIT0003],[@CIT0004] Understanding the rates and drivers for hospitalizations and other acute episodes of care is important when considering treatment choices, costs, later lines of therapy, and clinical course.

Symptoms related to CRC chemotherapy treatment are the primary reason for unexpected hospitalizations,[@CIT0005],[@CIT0006] although rates vary among previous studies. Hospitalization rates among younger patients (mean age 65 years) with any stage of CRC ranged from 12% to 53%.[@CIT0007],[@CIT0008] In older patients (age 70 years or older) with metastatic CRC (mCRC), hospitalization rates ranged from 22% in the first 30 days to 44% in the first 4 months following chemotherapy.[@CIT0009]--[@CIT0011] Jang et al reported 44% of patients with mCRC experienced a hospitalization for a serious adverse event.[@CIT0012] The highest overall rate of hospitalizations (78%) was reported for an elderly population with early-stage CRC.[@CIT0013]

Previous research on chemotherapy-related hospitalization among patients with CRC as well as other types of advanced cancer has also examined predictors of unplanned hospitalizations in specific populations, such as patients with certain types of cancer, in a particular age group, or treated at specific facilities.[@CIT0006]--[@CIT0008],[@CIT0013]--[@CIT0016] These studies found a higher risk of hospitalization among patients receiving 2 or more chemotherapy agents, women, those with comorbid conditions, and those with certain socioeconomic markers, such as non-White race, residence in a rural area, and low income. Additionally, researchers demonstrated patients in real-world settings had higher hospitalization rates than those reported in clinical trials,[@CIT0014],[@CIT0017] and they noted the need for further research on the real-world experience of patients receiving chemotherapy.[@CIT0017]

To address this research need, our study examined patients with stage IV mCRC undergoing first-line chemotherapy from a large commercial health insurer in the US. Our objective was to characterize the frequency of and possible reasons for the occurrence of hospitalizations in this population.

Methods {#S0003}
=======

This retrospective cohort study identified adults with mCRC using claims and clinical care data from the HealthCore Integrated Research Environment (HIRE). HIRE contains medical and pharmacy claims for 14 commercial health insurance plans across the United States. Researchers accessed data in the format of a limited data set for which data use agreements were in place with the covered entities in compliance with the Health Insurance Portability and Accountability Act (HIPAA) Privacy Rule.

We included patients with mCRC initiating treatment with a regimen that contained at least one of the five most frequently used first-line treatments for CRC (fluorouracil \[5-FU\], oxaliplatin, bevacizumab, irinotecan, and capecitabine) as observed in the database between June 23, 2014 and June 30, 2016, with the first claim set as the index date. All patients had ≥6 months of health insurance plan enrollment prior to index date (baseline period).

The primary endpoint was all-cause hospitalizations, including both inpatient stays and stand-alone emergency department (ED) visits without inpatient admission, occurring up to 30 days after the end of first-line chemotherapy. We analyzed the sample in aggregate as well as stratified by chemotherapy agents in the form of five overlapping cohorts. Baseline characteristics were described as absolute/relative frequencies for categorical variables, and means, standard deviations \[SD\], and/or medians with interquartile ranges (IQR) for continuous variables. We compared characteristics between patients with and without hospitalizations using *χ*^2^- and t-tests (univariate analysis). No statistical correction for multiple hypothesis testing was applied. The most common medical issues associated with inpatient hospitalizations were identified from the International Classification of Diseases, Ninth/Tenth Revision, Clinical Modification (ICD-9/10-CM) codes found in the primary diagnoses fields in the medical claims during the stay. Logistic regression was used for the multivariate evaluation determining baseline patient factors associated with the occurrence of ≥1 hospitalization.

Results {#S0004}
=======

Baseline Patient Characteristics {#S0004-S2001}
--------------------------------

A total of 717 patients were included in the study (285 hospitalized, 432 non-hospitalized) with a median follow-up time of 116 days (IQR 73--186). There were 34 distinct regimens used in the first-line setting ([[Appendix Table 1](https://www.dovepress.com/get_supplementary_file.php?f=222925.docx)]{.ul}). Mean age was 55.2 years and 58% were male ([Table 1](#T0001){ref-type="table"}). Eastern Oncology Cooperative Group (ECOG) performance status was most frequently 0 (44%) or 1 (39%). Approximately 25% of patients had undergone surgery in the 6 months prior to receiving first-line chemotherapy.Table 1Baseline Patient CharacteristicsOverall (N=717)Hospitalized (n=285)Non-Hospitalized (n=432)P-valueFollow-up (days), mean (SD)144.3 (101.30)151.9 (113.29)139.2 (92.33)0.320Age on index date (years), mean (SD)55.2 (9.21)55.6 (8.72)54.9 (9.51)0.426Male, n (%)412 (57.5)155 (54.4)257 (59.5)0.176Insurance Plan Type, n (%) PPO440 (61.4)174 (61.1)266 (61.6)0.888 HMO155 (21.6)52 (18.2)103 (23.8)0.075 CDHP122 (17.0)59 (20.7)63 (14.6)0.033Region of Patient Residence on Index Date, n (%)^a^ Northeast78 (10.9)29 (10.2)49 (11.3)0.623 Midwest257 (35.8)121 (42.5)136 (31.5)\<0.01 South197 (27.5)65 (22.8)132 (30.6)0.023 West177 (24.7)64 (22.5)113 (26.2)0.261ECOG Performance Status, n (%)^a^ 0313 (43.7)107 (37.5)206 (47.7)\<0.01 1281 (39.2)128 (44.9)153 (35.4)0.011 2+40 (5.6)26 (9.2)14 (3.2)\<0.01Tumor Characteristics, n (%)^a^ KRAS genotype mutation134 (18.7)53 (18.6)81 (18.8)0.959 KRAS genotype wildtype198 (27.6)81 (28.4)117 (27.1)0.695Cancer-Related Treatment, n (%) Surgery (total/partial colectomy)178 (24.8)69 (24.2)109 (25.2)0.757 Radiation therapy77 (10.7)28 (9.8)49 (11.3)0.521Metastasis, n (%) Liver368 (51.3)156 (54.7)212 (49.1)0.138 Lung160 (22.3)72 (25.3)88 (20.4)0.124 Brain9 (1.3)3 (1.1)6 (1.4)0.692^b^ Kidney8 (1.1)4 (1.4)4 (0.9)0.551^b^ Other203 (28.3)89 (31.2)114 (26.4)0.159QCI using non-cancer comorbidities, mean (SD)1.1 (1.18)1.2 (1.27)1.0 (1.12)0.078 Top 5 Comorbidity Components of the QCI, n (%) Mild liver disease310 (43.2)130 (45.6)180 (41.7)0.296 Chronic pulmonary disease100 (13.9)44 (15.4)56 (13.0)0.349 Diabetes without chronic complications99 (13.8)38 (13.3)61 (14.1)0.765 Peripheral vascular disease40 (5.6)14 (4.9)26 (6.0)0.528 Renal disease28 (3.9)17 (6.0)11 (2.5)0.021Colon Cancer-Related Comorbidities Colon or rectal polyp234 (32.6)91 (31.9)143 (33.1)0.743 Diverticulosis154 (21.5)55 (19.3)99 (22.9)0.248 Internal or external hemorrhoids126 (17.6)55 (19.3)71 (16.4)0.324 IBD70 (9.8)31 (10.9)39 (9.0)0.414 Angiodysplasia2 (0.3)1 (0.4)1 (0.2)0.767^b^[^1]

The most common first-line chemotherapeutic agents were 5-FU (79% of patients with at least one claim on the index date), oxaliplatin (67%), bevacizumab (58%), irinotecan (21%), and capecitabine (19%). The majority of patients (91%) received 2 or more agents. Liver was the most common site of metastasis (51%), followed by lung (22%). The most frequently reported comorbidities unrelated to cancer were mild liver disease (43%), chronic pulmonary disease (14%), and diabetes (14%). Colon or rectal polyp was the most frequently reported cancer-related comorbidity (33%), followed by diverticulosis (22%) and internal or external hemorrhoids (18%).

Hospitalizations During Follow-Up {#S0004-S2002}
---------------------------------

A total of 285 patients (40%) had ≥1 hospitalization, varying across treatment cohorts (40% 5-FU, 38% oxaliplatin, 42% bevacizumab, 49% irinotecan, 39% capecitabine; [Figure 1](#F0001){ref-type="fig"}). A small proportion (12%) of patients had ≥2 hospitalizations. Overall, 415 hospitalizations occurred, of which 260 were inpatient admissions and 155 were stand-alone ED visits. The mean time to the first hospitalization was 77 days (median 52, IQR 24--110), with a mean inpatient length of stay of 6 days (median 4, IQR 2--7). Infections/neutropenia (21%), bowel-related complications (17%), cardiac and circulatory disorders (9%), malnutrition (5%), pain (5%), and renal disease (2%) were identifiable issues associated with inpatient hospitalizations based on specific primary ICD diagnosis codes. In univariate analyses, insurance plan type, geographical location, higher ECOG scores, and renal disease were associated with hospitalization ([Table 1](#T0001){ref-type="table"}).Figure 1Frequency of hospitalization events (inpatient and/or ED).

Logistic regression showed no significant effect of most baseline patient demographic and clinical characteristics, as well as type of first-line agent used, on the occurrence of a hospitalization event ([Figure 2](#F0002){ref-type="fig"}). The only exception was an ECOG performance status of 1 or higher (OR 1.67; 95% CI 1.20--2.34; p=0.003).Figure 2Logistic regression results.**Note:** ^a^Region reference group comprised of either "West" or "missing".

Discussion {#S0005}
==========

Our real-world data analysis found that approximately 40% of patients with mCRC were hospitalized while undergoing first-line chemotherapy. The type of chemotherapy agent (among the top 5 most frequently used in this database) did not affect the rate of hospitalizations with statistical significance. However, it is striking that more than 30 distinct regimens were used when there are far fewer evidence-based regimens for first-line chemotherapy.[@CIT0018] Hospital stays were typically short and associated with infections, neutropenia, or bowel-related complications.

These data provide another estimate for oncology practices regarding the expected hospitalization rates associated with the wide variety of first-line systemic therapies used to treat mCRC. Our hospitalization rate of 40% is consistent with rates previously reported in younger patients with any stage of CRC[@CIT0007],[@CIT0012] as well as rates from studies in older patients with mCRC.[@CIT0009],[@CIT0011] Hospitalization rates reported in clinical trials often underestimate the effects of chemotherapy when used in a real-world population.[@CIT0017] Clinical trials typically enroll patients with younger average age, fewer comorbid conditions, less organ damage (e.g. renal function), and better performance status than those seen in daily practice, and trials provide more intensive care and follow-up than the community setting.

The data reported in our real-world study may help reduce unnecessary variation in chemotherapy treatment patterns for CRC, which are influenced by individual patient preferences and characteristics, and also by the treating physician.[@CIT0019] Treatment facilities may also use these data to develop anticipatory intervention plans to mitigate adverse events,[@CIT0020] support other quality improvement efforts, and prepare for alternative payment arrangements (for example, the Centers for Medicare and Medicaid Services is implementing value-based programs that provide incentive payments to physicians based on quality of service rather than quantity).[@CIT0021],[@CIT0022]

Our findings may also be useful during informed consent discussions to quantify the risks of hospitalization from first-line chemotherapy. For example, in the practice setting patients with ECOG=0 and ECOG=1 are often grouped based on the assumption of broadly similar clinical profiles. Our study found that ECOG ≥1 was associated with a 67% increase in the odds of hospitalization compared with patients with ECOG=0, suggesting that this part of the risk profile may actually diverge across the two groups. A previous study demonstrated improved patient outcomes -- including reductions in ED visits and hospitalizations -- when patients were engaged in monitoring their symptoms.[@CIT0020] Preparing patients more thoroughly for the effects of chemotherapy may therefore help improve outcomes.

Limitations {#S0006}
===========

Due to sample size constraints with less frequently used medications, not all possible first-line chemotherapy agents could be analyzed. Follow-up time was limited and did not necessarily include the entire first-line therapy course. Treatment choices may have been confounded by observed and unobserved baseline factors, limiting the ability to compare outcomes across agents. The database did not contain information about whether hospitalizations were planned or unplanned or whether patients' treatment regimens were changed during or after the hospitalization. The impact of rare comorbidities (such as renal disease in this study) on the risks of hospitalization requires further research. Patients were identified from a large US claims database, limiting the generalizability of the findings to other countries or other US populations, such as those without insurance or those on Medicaid. As treatments become increasingly tailored to patients via targeted therapies, the applicability of these findings to patients with specific biomarkers will need to be examined.

Conclusion {#S0007}
==========

A substantial proportion of patients with mCRC experienced a hospitalization while receiving chemotherapy. These data provide an initial estimate for oncology practices regarding the overall range of expected hospitalization rates associated with some of the currently used first-line systemic therapies for mCRC. Further research is needed to determine what proportion of these hospitalizations is potentially avoidable and what interventions can effectively reduce hospitalizations in patients with mCRC.
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[^1]: **Notes:** ^a^For the remainder of patients not listed in these rows, the corresponding information was missing or unknown. ^b^p-Values from *χ*^2^-tests as per protocol; confirmed to be non-significant with Fisher\'s exact test.

    **Abbreviations:** CDHP, consumer-driven health plan; ECOG, Eastern Cooperative Oncology Group; HMO, health maintenance organization; IBD, inflammatory bowel disease; KRAS, K-Ras protein; PPO, preferred provider organization; QCI, Quan--Charlson Comorbidity Index; SD, standard deviation.
